PhoenixMD selected to present at "Dose of the Valley" in San Francisco

February 19, 2016 — Phoenix Molecular Designs was selected to present at Dose of the Valley in San Francisco on February 9th and 10th, 2016. Dose of the Valley is a two-day program organized by the C100, BDC Venture Capital and the Canadian Consulate in San Francisco. The annual by invitation-only event connects Canada’s most promising life science companies from biopharma, medical device and health IT sectors through roundtable discussions, industry-led workshops, one-on-one mentorship, an investor/partnering pitch session, and a networking reception. Out of 60 applicants across Canada, only 20 were selected to attend by a high-level review committee.

Silicon Valley in San Francisco represents a global hub for life sciences. With a significant presence of pharmaceutical companies, health care providers, and venture capital, this region holds tremendous opportunity for Canadian companies. This is a unique opportunity for innovative Canadian companies to engage with valuable industry contacts, gain visibility, and develop productive relationships within this top global innovation ecosystem.

“As a leader in cancer therapeutics, we are very pleased to have been selected to join this program and present innovative Canadian-developed technology,” says Sandra Dunn, CEO, PhoenixMD. The Dose of the Valley event connected PhoenixMD with large pharmaceutical companies, and facilitated one-on-one meetings. It provided exposure to venture capital and private investment opportunities. Finally, the Dose of the Valley created partnership opportunities with companies based in the United States and Canada.